Skip to content

Interim report January – March 2023: 2023 STARTED VERY STRONGLY


Net sales amounted to SEK 229.1 million (159.1), corresponding to an increase of 44 percent compared with the corresponding period in the preceding year.

License revenues roughly doubled to SEK 70.6 million (35.7) and accounted for 31 percent of net sales (22).

Operating profit amounted to SEK 53.3 million (20.0).

Net profit amounted to SEK 49.8 million (16.5), corresponding to earnings per share of SEK 0.98 (0.32).

Cash flow from operating activities amounted to SEK 60.5 million (11.1). As of March 31, 2023, cash and cash equivalents amounted to SEK 482.1 million (329.9).

Gothenburg, Sweden, May 16, 2023
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation